Your session is about to expire
← Back to Search
MT-8421 + Nivolumab for Advanced Solid Cancer Types
This trial studies a new drug to treat advanced solid cancers by targeting and depleting cells associated with the tumor microenvironment.
- Oral Squamous Cell Carcinoma
- Non-Small Cell Lung Cancer
- Cervical Cancer
- Liver Cancer
- Microsatellite Instability
- Lynch Syndrome
- Esophageal Cancer
- Kidney Cancer
- Bladder Cancer
- Squamous Cell Carcinoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you please elucidate the hazard of Part A- Dose Escalation Monotherapy for patients?
"The safety of Part A- Dose Escalation Monotherapy is initially estimated to be a 1 due to this being an early Phase 1 trial, meaning that available data supporting its efficacy and safety is limited."
Are individuals being asked to join this research endeavor at the present time?
"According to clinicaltrials.gov, this research exploration is currently recruiting participants - the trial was initially published on September 1st 2023 and had its most recent update released five days later."
How widespread is the implementation of this experiment?
"This medical research is currently taking place at Horizon Oncology Research in Lafayette, Indiana, Washingtonn Oncology Research in Lafayette, Indiana, Washington University in St. Louis and Weill Cornell Medicine in New York City. Additionally, 5 other sites are participating this trial as well."
What are the major goals of this experimental endeavor?
"According to the trial's sponsor Molecular Templates, Inc., this medical study will be measuring its primary outcome over a 28 day cycle interval; that is to confirm the recommended Phase 2 dose (RP2D) of MT-8421 both as monotherapy and in conjunction with nivolumab. Furthermore, secondary objectives such as duration of response, time to response, and progression-free survival are being used to assess preliminary efficacy."
Share this study with friends